Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02029950 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia-2
High Risk Myelodysplastic Syndrome
Myeloproliferative Neoplasm

Interventions

DRUG: Cytarabine
DRUG: Daunorubicin Hydrochloride
DRUG: Etoposide
DRUG: Idarubicin Hydrochloride
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Pomalidomide

Sponsor

National Cancer Institute (NCI)